Beijing Hotgen Biotech Co Ltd
SSE:688068
Intrinsic Value
Beijing Hotgen Biotech Co., Ltd. engages in the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. [ Read More ]
The intrinsic value of one Beijing Hotgen Biotech Co Ltd stock under the Base Case scenario is 170.29 CNY. Compared to the current market price of 30.22 CNY, Beijing Hotgen Biotech Co Ltd is Undervalued by 82%.
Valuation Backtest
Beijing Hotgen Biotech Co Ltd
Run backtest to discover the historical profit from buying and selling Beijing Hotgen Biotech Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Beijing Hotgen Biotech Co Ltd's business.
What risks and challenges
does Beijing Hotgen Biotech Co Ltd face in the near future?
Summarize the latest earnings report
of Beijing Hotgen Biotech Co Ltd.
Provide P/E
for Beijing Hotgen Biotech Co Ltd and its competitors.
Balance Sheet Decomposition
Beijing Hotgen Biotech Co Ltd
Current Assets | 931.3m |
Cash & Short-Term Investments | 468.4m |
Receivables | 121.6m |
Other Current Assets | 341.2m |
Non-Current Assets | 2.7B |
Long-Term Investments | 1.3B |
PP&E | 1.1B |
Intangibles | 54.2m |
Other Non-Current Assets | 158.2m |
Current Liabilities | 169.1m |
Accounts Payable | 113m |
Accrued Liabilities | 21.6m |
Other Current Liabilities | 34.5m |
Non-Current Liabilities | 34.1m |
Long-Term Debt | 12.6m |
Other Non-Current Liabilities | 21.5m |
Earnings Waterfall
Beijing Hotgen Biotech Co Ltd
Revenue
|
954.3m
CNY
|
Cost of Revenue
|
-471.6m
CNY
|
Gross Profit
|
482.7m
CNY
|
Operating Expenses
|
-650.4m
CNY
|
Operating Income
|
-167.7m
CNY
|
Other Expenses
|
65.3m
CNY
|
Net Income
|
-102.4m
CNY
|
Free Cash Flow Analysis
Beijing Hotgen Biotech Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Beijing Hotgen Biotech Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Beijing Hotgen Biotech Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beijing Hotgen Biotech Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Beijing Hotgen Biotech Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beijing Hotgen Biotech Co Ltd
Shareholder Return
Price
Beijing Hotgen Biotech Co Ltd
Average Annual Return | 29.91% |
Standard Deviation of Annual Returns | 101.98% |
Max Drawdown | -84% |
Market Capitalization | 2.8B CNY |
Shares Outstanding | 92 268 766 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Beijing Hotgen Biotech Co., Ltd. engages in the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The company is headquartered in Beijing, Beijing and currently employs 1,019 full-time employees. The company went IPO on 2019-09-30. The firm's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The firm primarily conducts its businesses in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Beijing Hotgen Biotech Co Ltd stock under the Base Case scenario is 170.29 CNY.
Compared to the current market price of 30.22 CNY, Beijing Hotgen Biotech Co Ltd is Undervalued by 82%.